Recursion Pharmaceuticals, Inc. RXRX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s stock issuance proceeds?
- Recursion Pharmaceuticals, Inc. (RXRX) reported stock issuance proceeds of $0 in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s stock issuance proceeds changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $41.02M to $0.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s stock issuance proceeds?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a 3.4% compound annual growth rate (CAGR), from $462.9M to $528.86M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.